Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.71 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.71 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.44 |
| ▸ | TCF7L2 | Q9NQB0 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27634905 | 0.93 | PTGDR2 (0.65) | TBXA2RPTGDRPTGDR2HIF1AEPAS1 | |
| SCHEMBL6878036 | 0.93 | PTGDR2 (0.65) | TBXA2RPTGDRPTGDR2HIF1AEPAS1 | |
| SCHEMBL27655923 | 0.92 | PTGDR2 (0.63) | TBXA2RPTGDRPTGDR2HIF1AEPAS1 | |
| SCHEMBL27634910 | 0.91 | PTGDR2 (0.62) | TBXA2RPTGDRPTGDR2HIF1AEPAS1 | |
| SCHEMBL12556772 | 0.84 | PTGDR2 (0.80) | TBXA2RPTGDRPTGDR2HIF1AEPAS1 | |
| SCHEMBL12569021 | 0.83 | PTGDR2 (0.82) | TBXA2RPTGDRPTGDR2HIF1AEPAS1 | |
| Bi-671800 SCHEMBL12415807 | 0.83 | PTGDR2 (1.00) | TBXA2RPTGDRPTGDR2HIF1AEPAS1 | |
| Bi-671800 SCHEMBL12415720 | 0.83 | PTGDR2 (1.00) | TBXA2RPTGDRPTGDR2HIF1AEPAS1 | |
| Bi-671800 SCHEMBL2788886 | 0.83 | PTGDR2 (1.00) | TBXA2RPTGDRPTGDR2HIF1AEPAS1 | |
| Bi-671800 SCHEMBL12415799 | 0.83 | PTGDR2 (1.00) | TBXA2RPTGDRPTGDR2HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504319-A1 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2012-10-03 | — | — | EP | claimed |
| WO-2011066176-A1 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-03 | — | — | WO | claimed |
| EP-2598143-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| EP-2598145-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| EP-2451787-B1 | POLYMORPH OF [4,6-BIS(DIMETHYLAMINO)-2-(4-{[4-(TRIFLUOROMETHYL)BENZOYL]AMINO}BENZYL)PYRIMIDIN-5-YL] | BOEHRINGER INGELHEIM INT (DE) | 2013-04-24 | — | — | EP | disclosed |
| US-20120302584-A1 | NOVEL SALTS FORMS OF PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302584-A1 | NOVEL SALTS FORMS OF PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| EP-2504319-A1 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2012-10-03 | — | — | EP | disclosed |
| EP-2504319-A1 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2012-10-03 | — | — | EP | disclosed |
| EP-2504318-A2 | CRYSTALLINE SALT FORMS OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2012-10-03 | — | — | EP | disclosed |
| EP-2504318-A2 | CRYSTALLINE SALT FORMS OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066176-A1 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011066176-A1 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011066147-A2 | NOVEL SALT FORMS OF PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011005645-A1 | POLYMORPH OF [4,6-BIS(DIMETHYLAMINO)-2-(4-{[4-(TRIFLUOROMETHYL)BENZOYL]AMINO}BENZYL)PYRIMIDIN-5-YL] | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005645-A1 | POLYMORPH OF [4,6-BIS(DIMETHYLAMINO)-2-(4-{[4-(TRIFLUOROMETHYL)BENZOYL]AMINO}BENZYL)PYRIMIDIN-5-YL] | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-13 | — | — | WO | disclosed |
| EP-2176240-A1 | AMINE SALTS OF A CRTH2 ANTAGONIST | Actimis Pharmaceuticals, Inc., (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-2170838-A1 | PARTICULATES OF A CRTH2 ANTAGONIST | Actimis Pharmaceuticals, Inc., (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156781-A1 | AMINE SALTS OF A CRTH2 ANTAGONIST | ACTIMIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156780-A1 | PARTICULATES OF A CRTH2 ANTAGONIST | ACTIMIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302584-A1 | NOVEL SALTS FORMS OF PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE | SLC5A2, MDH1, GRIA2 | TBXA2R 1172/4885PTGDR 2375/4885PTGDR2 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.